For example, TN breast cancers demonstrate diverse histological patterning and few consistently recurring mutational trends aside from TP53, PTEN, and PICK3CA, the latter concern being a large obstacle for developing targeted therapies [4]. This evidence concerns the gene TP53 and breast carcinoma.